Sensorion (FR0012596468 – ALSEN), a clinical-stage biotech company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, announced that the Independent Ethics Committee of Strasbourg (France) has reviewed and approved a list of additional centers that will participate in the ongoing Phase 2 study for SENS- 401 in Sudden Sensorineural Hearing Loss (SSNHL). Inclusion of voluntary military patients on these new sites will start after final administrative steps are carried out, according to Sensorion.
The new centers will recruit volunteer military personnel exposed to impulse noise during their professional activities and suffering from hearing loss. The participation of the French Army in the Phase 2 study makes this “the largest military trial ever conducted in France,” according to the company’s announcement.
The PATRIOT consortium—led by Sensorion and also comprising the French Biomedical Research Center (IRBA), Institut Pasteur, and Electronique du Mazet 1—has been awarded €10.8m ($11.7 million USD) non-dilutive funding from the French government, with Sensorion eligible to receive up to €5.6m ($6.1 million USD) to support SENS-401 clinical development for SSNHL.